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Gadolinium deposition in the brain: another concern regarding 
gadolinium-based contrast agents 
Nevzat Karabulut Life is continuously confronting us with new issues and sometimes breaking our rou-tine. One case in point is the curious way radiologists’ knowledge about the benefits and risks of gadolinium-based contrast agents (GBCAs) continues to evolve. Signifi-
cantly improving detection and characterization of lesions in a broad spectrum of diseases, 
GBCAs have become integral aides to magnetic resonance imaging (MRI) for almost three 
decades. Because free gadolinium is toxic, it needs to be chelated with a ligand ion to facil-
itate its excretion through the kidneys. Currently available GBCAs have different chemical 
properties primarily determined by the chelating ligand molecule. These agents had initial-
ly been believed to be risk-free with rapid elimination from the body, and administered to 
millions of patients somewhat indiscreetly for over a decade after the clinical approval of 
gadopentate dimeglumine in 1988. This naive belief was disproved by a string of studies 
revealing a relationship between the use of GBCAs and the development of nephrogenic 
systemic fibrosis (NSF) in 2006 (2, 3). The accrued data convincingly showed a causal link 
between GBCAs and the risk of NSF in patients with severely compromised renal function 
(glomerular filtration rate <30 mL/min). Due to insufficient excretion of GBCA in patients 
with poor renal function, the administered contrast material (gadolinium chelate) stays 
long enough in the body to pose the risk of dissociation (dechelation) which consequent-
ly triggers the cascade of events resulting in NSF. An editorial published in the December 
2006 issue of this journal addressed the issue of NSF and provided some timely recom-
mendations (4). Further studies revealed that the chemical structure of GBCAs matters in 
the development of NSF, and the risk is much higher with nonionic linear chelates, such as 
gadodiamide and gadoversetamide, due to rapid release of gadolinium (dechelation) in 
these agents. Conversely, macrocyclic GBCAs are more resistant to dechelation and con-
sidered to be more stable. These studies modified the practice of intravenous MRI contrast 
agent use and paved the way for the creation of new standards in the use of GBCAs. Many 
international and national authorities established guidelines for the use of GBCAs in MRI. 
These guidelines primarily categorized agents into three categories as low risk (macrocyclic 
agents), intermediate risk (ionic-linear chelates) and high risk (nonionic-linear chelates) for 
the development of NSF. Adherence to these guidelines and adoption of new contrast-en-
hanced MRI protocols, which restrict the administration of high-risk GBCAs only to subjects 
with normal renal function and replace these agents with more stable GBCAs in high-risk 
patients, resulted in a dramatic decline in the incidence of NSF (5). Nevertheless, it should be 
emphasized that there are considerable differences between GBCAs with similar structure. 
For instance, no unconfounded NSF case has been reported following administration of 
ionic-linear gadobenate dimeglumine whereas two NSF cases were reported after uncon-
founded administration of nonionic-macrocyclic gadobutrol (6).
In 2014, radiologists (as well as clinicians) were in for another stunning report, this time of 
a study performed in Japan (7) implying deposition of gadolinium in the brain manifested 
as dose-related T1 shortening in the globus pallidus and the dentate nuclei in patients who 
had been administered repeated previous doses of gadodiamide and/or gadopentetate di-
meglumine. This novel observation was subsequently confirmed by Errante et al. (8) who 
reported dose-dependent T1 shortening in the dentate nucleus in subjects with normal 
kidney and liver function who had serial prior administration of gadodiamide. Two recent 
studies performed on autopsy specimens proved that T1 shortening results from gadolini-
um retention in neuronal tissues of the global pallidus, thalamus, dentate nucleus, and pons 
(9, 10). It was shown that gadolinium deposition was detectable with as few as four lifetime 
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doses of gadodiamide in all patients regard-
less of renal or hepatobiliary dysfunction 
(10). The retained gadolinium was shown to 
accumulate mainly in the endothelial walls 
while a smaller amount of it did cross the 
blood-brain barrier and deposited within 
neuronal interstitium.
Similar to the link between NSF and GB-
CAs, the growing body of data indicates 
that the molecular structure of GBCAs also 
matters in T1 shortening in the neuronal 
tissue. Two recent studies reported in 2015 
from Japan (11) and Germany (12) demon-
strated that high signal intensity in dentate 
nucleus was associated with the repeated 
previous administrations of the ionic-lin-
ear agent (gadopentetate dimeglumine in 
both studies), but not with the repeated 
prior administrations of the nonionic-mac-
rocyclic (gadoteridol) and ionic-macrocy-
clic (gadoterate meglumine) agents. These 
findings imply that the observed T1 hyper-
intensity may represent a consequence of 
the dissociation of gadolinium from its li-
gand molecule.
What is the responsibility of radiologists 
at this stage? What has been learned from 
the GBCA-NSF linkage mostly holds true for 
gadolinium retention in intracranial neuro-
nal tissues. The chemical structure of the 
GBCAs is directly related to retention; the 
amount is lowest in macrocyclic GBCAs, 
high in ionic-linear GBCAs, and highest in 
nonionic-linear GBCAs (6). More worrisome 
is that gadolinium deposition occurs in all 
subjects exposed to GBCA regardless of re-
nal or hepatobiliary dysfunction. Although 
the clinical significance of gadolinium ac-
cumulation remains unclear, the reported 
findings are troublesome and radiologists 
need to take this issue into account and em-
ploy caution when administering GBCAs. As 
gadolinium deposition in brain may occur 
even in subjects with normal renal and 
hepatobiliary function, in contrast to NSF, 
we need to avoid overusing contrast-en-
hanced MRI, and justify that each gadolin-
ium-enhanced MRI is truly indicated. Then, 
we should sparingly choose more stable 
GBCAs in each subject to reduce the risk 
of potential long-term detrimental effects. 
Since neuronal gadolinium deposition is 
significantly dose-dependent, we should 
make every effort to administer the low-
est reasonable amount of GBCA. Children 
and young adults deserve extra attention 
in using GBCAs, and appropriate measures 
should be taken to minimize the cumula-
tive gadolinium deposition over a patient’s 
lifetime. Surprises are unavoidable in the 
vagaries of life, mechanisms of which are 
poorly understood despite all the advances 
in science. Always bearing in mind the dic-
tum “primum non nocere”, we need to em-
ploy caution and carefully weigh the risks 
and benefits of our decision to use GBCAs. 
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